EUVIMEDEUVIMED entdecken
Crossref

Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy

P Connor Johnson, Jeremy S Abramson, Ann S LaCasce, Philippe Armand, Jeffrey Barnes, Reid W Merryman, Jacob Soumerai, Ephraim Hochberg, Ronald W Takvorian, Caron A Jacobson, Jennifer L Crombie, David C Fisher und 8 weitere

Journal of the National Comprehensive Cancer Network · 2025

DOI: 10.6004/jnccn.2024.7082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von P Connor Johnson und 19 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Hematology & Oncology, Mass General Hospital Cancer Center, Boston, MA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Quality of Life, Lymphoma, Non-Hodgkin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aggressive non-Hodgkin lymphoma (aNHL) is more common in older adults. Although chemoimmunotherapy can yield durable remissions, it is also associated with significant toxicities. Despite this, longitudinal studies assessing patient-reported outcomes (PROs) with chemoimmunotherapy in this population are lacking. Patients and Methods: We conducted a longitudinal study of 105 adults aged ≥65 years who initiated up-front chemoimmunotherapy for aNHL across 2 academic centers and their community affiliates between September 2020 and January 2023. Quality of life (QoL) was assessed using the Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym), physical symptoms via the revised Edmonton Symptom Assessment Scale (ESAS-r), and psychological symptoms with the Hospital Anxiety and Depression Scale (HADS). Assessments were performed at baseline; 6, 12, 18, and 24 weeks post–therapy initiation; and 1 year post–therapy initiation. Frailty status was evaluated at baseline using the Fondazione Italiana Linfomi geriatric assessment (GA) and the Vulnerable Elders Survey-13 (VES-13). Linear mixed models were used to examine the trajectory of PROs over time, and linear regression was employed to identify factors associated with QoL at 1 year.

Results

The median patient age was 73 years (range, 64–99), with 41.9% aged ≥75 years. Most patients (53.8%) had an age-adjusted International Prognostic Index (IPI) of 2/3, and 70.5% had diffuse large B-cell lymphoma. Overall, 50.5% and 45.7% were identified as frail or vulnerable on GA and VES-13, respectively. Longitudinal QoL, physical symptoms, anxiety, and depression all significantly improved over time (all P ≤.001). QoL improved regardless of age category (65–74 vs ≥75 years) or frailty status. In multivariate analyses, being married/living with partner was associated with better QoL at 1 year (β=11.6; P =.026), whereas frailty on GA (β= −9.90; P =.036) was associated with worse QoL.

Conclusions

Older adults with aNHL receiving chemoimmunotherapy experienced significant and durable improvement in QoL, physical symptoms, and psychological health up to 1 year post–therapy initiation, irrespective of age or frailty status. However, frailty was associated with worse QoL at 1 year post–therapy initiation. These findings underscore the importance of integrating GAs into treatment planning for older adults with aNHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresQuality of LifeLymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansAgedMaleFemaleLongitudinal StudiesAged, 80 and overGeriatric Assessment

Autor:innen und Institutionen

  • 1Division of Hematology & Oncology, Mass General Hospital Cancer Center, Boston, MA.
  • 2Harvard Medical School, Boston, MA.
  • 3Division of Lymphoma, Dana-Farber Cancer Institute, Boston, MA.
  • 4The Warren Albert Medical School, Brown University, Providence, RI.
  • 5Department of Psychiatry, Massachusetts General Hospital, Boston, MA.
  • 6Duke School of Medicine, Durham, NC.

Zitieren

APA

Johnson, P. C., Abramson, J. S., LaCasce, A. S., Armand, P., Barnes, J., Merryman, R. W., Soumerai, J., Hochberg, E., Takvorian, R. W., Jacobson, C. A., Crombie, J. L., Fisher, D. C., Schwartz, J., Friedman, R. S., Stacey, J., Yang, D., Coffey, B., Markowitz, N., Odejide, O. O., & El-Jawahri, A. (2025). Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7082

Vancouver

Johnson PC, Abramson JS, LaCasce AS, Armand P, Barnes J, Merryman RW, et al. Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2024.7082

BibTeX
@article{Johnson2025,
  author = {Johnson, P Connor and Abramson, Jeremy S and LaCasce, Ann S and Armand, Philippe and Barnes, Jeffrey and Merryman, Reid W and Soumerai, Jacob and Hochberg, Ephraim and Takvorian, Ronald W and Jacobson, Caron A and Crombie, Jennifer L and Fisher, David C and Schwartz, Joel and Friedman, Robb S and Stacey, Julia and Yang, Daniel and Coffey, Bridget and Markowitz, Netana and Odejide, Oreofe O and El-Jawahri, Areej},
  title = {Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  doi = {10.6004/jnccn.2024.7082}
}
Kostenlos starten →